Andrew Feigin

Andrew Feigin publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Andrew Feigin sits on this spectrum.

Andrew Feigin D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew Feigin sits on this spectrum.

Best Publications

• Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

  Michael G Kaplitt;Andrew Feigin;Andrew Feigin;Chengke Tang;Helen L Fitzsimons

  1306
  Citations

• AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

  Peter A LeWitt;Ali R Rezai;Maureen A Leehey;Steven G Ojemann

  750
  Citations

• FDG PET in the differential diagnosis of parkinsonian disorders

  Thomas Eckert;Anna Barnes;Vijay Dhawan;Vijay Dhawan;Vijay Dhawan;Steve Frucht

  489
  Citations

• Changes in network activity with the progression of Parkinson's disease.

  Chaorui Huang;Chengke Tang;Andrew Feigin;Martin Lesser

  451
  Citations

• Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis

  Chris C Tang;Kathleen L Poston;Kathleen L Poston;Kathleen L Poston;Thomas Eckert;Thomas Eckert;Andrew Feigin

  409
  Citations

• The role of radiotracer imaging in Parkinson disease

  B. Ravina;D. Eidelberg;J. E. Ahlskog;R. L. Albin

  385
  Citations

• Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

  S. M. Hersch;S. Gevorkian;K. Marder;C. Moskowitz

  374
  Citations

• A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit

  M Flint Beal;David Oakes;Ira Shoulson

  344
  Citations

• Dyskinesia after fetal cell transplantation for parkinsonism: a PET study.

  Yilong Ma;Yilong Ma;Andrew Feigin;Andrew Feigin;Vijay Dhawan;Vijay Dhawan;Masafumi Fukuda

  303
  Citations

• Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease

  Andrew Feigin;Michael G. Kaplitt;Chengke Tang;Tanya Lin

  282
  Citations

• Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial

  Samuel Frank;Claudia M. Testa;David Stamler;Elise Kayson

  243
  Citations

• An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease

  Dennis J. Zgaljardic;Joan C. Borod;Nancy S. Foldi;Paul J. Mattis

  241
  Citations

• Metabolic correlates of levodopa response in Parkinson's disease.

  A. Feigin;M. Fukuda;V. Dhawan;S. Przedborski

  231
  Citations

• Metabolic Network Abnormalities in Early Huntington’s Disease: An [18F]FDG PET Study

  Andrew Feigin;Klaus L. Leenders;James R. Moeller;John Missimer

  224
  Citations

• The metabolic anatomy of Tourette's syndrome.

  D. Eidelberg;J. R. Moeller;A. Antonini;K. Kazumata

  224
  Citations

• Thalamic metabolism and symptom onset in preclinical Huntington's disease.

  A. Feigin;C. Tang;Y. Ma;P. Mattis

  223
  Citations

• Abnormal metabolic networks in atypical parkinsonism.

  Thomas Eckert;Thomas Eckert;Chengke Tang;Yilong Ma;Yilong Ma;Nathaniel Brown

  212
  Citations

• Trinucleotide repeat length and progression of illness in Huntington's disease.

  K Kieburtz;M MacDonald;C Shih;A Feigin

  195
  Citations

• Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT

  Robert B. Innis;Kenneth L. Marek;Kim Sheff;Sami Zoghbi

  181
  Citations

• Abnormal metabolic network activity in REM sleep behavior disorder

  Florian Holtbernd;Jean-François Gagnon;Ron B. Postuma;Yilong Ma

  178
  Citations